Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT06904053 · ClinicalTrials.gov registry record

Metagenomics Next-generation Sequencing Approach to Detect Microbial DNA/RNA Overtime in Individuals Undergoing Hematopoietic Stem Cell Transplant

A clinical trial of Hematopoietic Stem Cell Transplantation, sponsored by National Institutes of Health Clinical Center (CC).

Recruiting
Registry status
30
Enrollment target
1
Study location

NCT06904053: Recruiting study of Hematopoietic Stem Cell Transplantation, sponsored by National Institutes of Health Clinical Center (CC).

NCT06904053 is a study of Hematopoietic Stem Cell Transplantation that is actively recruiting participants, run by National Institutes of Health Clinical Center (CC). The registered enrollment target is 30 participants, below the 9,789-participant average among 26 other Hematopoietic Stem Cell Transplantation trials with a reported enrollment target (100% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT06904053, a study of Hematopoietic Stem Cell Transplantation, is actively recruiting participants, sponsored by National Institutes of Health Clinical Center (CC).

RECRUITING
Registry status
30 participants
Enrollment target
1
Study location

Study Summary

Infections are a major cause of morbidity and mortality in patients undergoing hematopoietic stem cell transplant (HSCT). The purpose of this study is to evaluate if metagenomic next-generation sequencing (mNGS) can detect microbial signatures in people undergoing HSCT, and if microbial identification can be correlated with clinical features of infection (e.g., fever). Participants undergoing HSCT as part of other studies at the NIH Clinical Center (CC) will provide blood before the transplant and through 6 months after. Total nucleic acid will be extracted from plasma and subjected to mNGS. The primary objective of this study is to investigate if by using plasma and an mNGS approach, we can detect bacterial, fungal, protozoan, or viral DNA/RNA over time, in immunocompromised patients undergoing transplantation. Secondary objectives are to: (1) To correlate microbial identification with episodes of fever or clinical suspicion of infection; and to (2) correlate change in microbial signatures in patients with suspected immune reconstitution inflammatory syndrome. The study is conducted at the NIH Clinical Center. Participants, aged 3 years and older, on other research studies at the NIH CC who are undergoing HSCT are invited to take part of this study. Expected participation is up to six months.

Primary Outcome

Research blood draw at screening, during fever episodes and at follow up days 30, 100 and 180 (+/- 7 days).

Study Locations (1)

Maryland

  • National Institutes of Health Clinical Center - Bethesda

Trial Details

FieldValue
Enrollment Target 30 participants
Start Date 2025-04-09
Est. Completion 2030-12-30

What NCT06904053 shows while recruiting

NCT06904053 is an observational study that tracks outcomes without assigning an intervention. The registry caps enrollment at 30 participants, a relatively small participant target, below the 9,789-participant average among 26 other Hematopoietic Stem Cell Transplantation trials with a reported enrollment target (100% lower).

The record links to 1 condition, with Hematopoietic Stem Cell Transplantation appearing as the primary indexed condition, and to 0 interventions.

NCT06904053 reports a single indexed study location in Maryland.

Frequently Asked Questions

What is clinical trial NCT06904053 about?

NCT06904053 is a clinical study titled "Metagenomics Next-generation Sequencing Approach to Detect Microbial DNA/RNA Overtime in Individuals Undergoing Hematopoietic Stem Cell Transplant". Infections are a major cause of morbidity and mortality in patients undergoing hematopoietic stem cell transplant (HSCT). The purpose of this study is to evaluate if metagenomic next-generation sequencing (mNGS) can detect microbial signatures in people undergoing HSCT, and if microbial identificati...

What is the current status of trial NCT06904053?

This trial is currently recruiting. The enrollment target is 30 participants. The study started on 2025-04-09. Estimated completion is 2030-12-30.

What conditions does trial NCT06904053 study?

This clinical trial studies the following conditions: Hematopoietic Stem Cell Transplantation.

Who is sponsoring clinical trial NCT06904053?

This trial is sponsored by National Institutes of Health Clinical Center (CC), which has 338 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT06904053 being conducted?

This trial has 1 study location across Maryland. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Hematopoietic Stem Cell Transplantation

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Where NCT06904053's enrollment target sits among peer trials

30 19th of 26 higher than 7 of 26 other Hematopoietic Stem Cell Transplantation trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other Hematopoietic Stem Cell Transplantation trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT00977977 · 30 participants · Phase 2

    Rituximab Plus Cyclosporine in Idiopathic Membranous Nephropathy

  • NCT01459107 · 30 participants · Phase 2

    Human Upper Extremity Allotransplantation

  • NCT01666080 · 30 participants · NA

    Second or Greater Allogeneic Hematopoietic Stem Cell Transplant Using Reduced Intensity Conditioning (RIC)

  • NCT01720836 · 30 participants · Phase 1

    Study of the Immune Response of MUC1 (Mucin1) Peptide Vaccine for Non-small Cell Lung Cancer

Similar registry start date

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

  • NCT07125183 · started 2026-12 · Phase 2

    Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma

  • NCT07292298 · started 2026-11 · Phase 2

    Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates

  • NCT04263285 · started 2026-10 · NA

    Treatment of Depression Post-SCI

Source: ClinicalTrials.gov NCT06904053, the US trial registry maintained by the National Library of Medicine. NCT06904053 (small enrollment · single site footprint · recruiting) retrieved and formatted by PlainTrial, see methodology.